![B7-H4](https://www.adcreviews.com/wp-content/uploads/2022/09/B7-H4-1-300x164.png)
Mersana Announces Fast Track Grant from FDA for Its Targeted B7-H4
On September 12, Mersana announced that its ADC product XMT-1660 targeting was granted Fast Track designation by the FDA for the treatment of adult patients
On September 12, Mersana announced that its ADC product XMT-1660 targeting was granted Fast Track designation by the FDA for the treatment of adult patients